Ticker Details
Ardelyx, Inc. Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases.
IPO Date:	June 19, 2014
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.25 | 3.54%
Avg Daily Range (30 D):	$0.13 | 2.68%
Avg Daily Range (90 D):	$0.14 | 2.55%

Institutional Daily Volume
Avg Daily Volume:	2.5M
Avg Daily Volume (30 D):	3.51M
Avg Daily Volume (90 D):	3.45M

Trade Size
Avg Trade Size (Sh.):	251
Avg Trade Size (Sh.) (30 D):	174
Avg Trade Size (Sh.) (90 D):	159

Institutional Trades
Total Institutional Trades:	1,865
Avg Institutional Trade:	$2.18M
Avg Institutional Trade (30 D):	$2.05M
Avg Institutional Trade (90 D):	$2.23M
Avg Institutional Trade Volume:	.42M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.91M
Avg Closing Trade (30 D):	$2.4M
Avg Closing Trade (90 D):	$3.09M
Avg Closing Volume:	537.42K

News

Jul 29, 2026 @ 2:46 PM New Cross-Study Analysis from Spherix Global Insig... Source: Spherix Global Insights

Apr 3, 2026 @ 3:11 PM Ardelyx President and CEO Sells 41,000 Shares for ... Source: Sarah Sidlow

Apr 1, 2026 @ 12:01 PM Rajani Dinavahi, MD, Appointed Chief Medical Offic... Source: Na

Feb 5, 2026 @ 1:00 PM Ardelyx to Report Full Year and Fourth Quarter 202... Source: Na

Jan 23, 2026 @ 5:56 PM Breaking Barriers: How 2026’s Top Clinical ... Source: Equity Insider

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-.23	$-.07	$-.15
Diluted EPS	$-.23	$-.07	$-.15
Revenue	$450.89M	$120.88M	$94.47M
Gross Profit	$425.49M	$115.12M	$89.66M
Net Income / Loss	$-55.7M	$-16.72M	$-37.61M
Operating Income / Loss	$-35.45M	$-12.43M	$-32.79M
Cost of Revenue	$25.4M	$5.76M	$4.81M
Net Cash Flow	$7.15M
PE Ratio